(MOLN)
4.04
-0.16 (-3.81%)
Apr 28, 2025, 11:52 AM - Market open
-3.81% (1D)
| Bid | 4 |
| Market Cap | 148.97M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -1.92 |
| PE Ratio (ttm) | -2.1 |
| Forward PE | n/a |
| Analyst | n/a |
| Ask | 4.26 |
| Volume | 75,350 |
| Avg. Volume (20D) | 8,298 |
| Open | 4.48 |
| Previous Close | 4.20 |
| Day's Range | 4.00 - 4.48 |
| 52-Week Range | 3.51 - 12.70 |
| Beta | undefined |
1 day ago
Molecular Partners shares are trading higher after...
Unlock content with
Pro Subscription
5 months ago
Molecular Partners shares are trading higher after the company announced its radio-DARPin therapy candidate MP0712 was supported by in vivo data presented at the European Association of Nuclear Medicine Congress. The first-in-human start and initial clinical data are expected in 2025.
